Does One Size Fit All? - Refining Parenteral Anticoagulant Therapy According to Body Weight.
作者信息
Furtado Remo Holanda de Mendonça
机构信息
Brazilian Clinical Research Institute, São Paulo, SP - Brasil.
Academic Research Organization, Hospital Sírio Libanês, São Paulo, SP - Brasil.
出版信息
Arq Bras Cardiol. 2025 Jun 16;122(4):e20250251. doi: 10.36660/abc.20250251. eCollection 2025.
Abstract
摘要
相似文献
1
Does One Size Fit All? - Refining Parenteral Anticoagulant Therapy According to Body Weight.一刀切是否可行？——根据体重优化肠外抗凝治疗
Arq Bras Cardiol. 2025 Jun 16;122(4):e20250251. doi: 10.36660/abc.20250251. eCollection 2025.
2
Nutrition support in hospitalised adults at nutritional risk.住院有营养风险的成年人的营养支持。
Cochrane Database Syst Rev. 2017 May 19;5(5):CD011598. doi: 10.1002/14651858.CD011598.pub2.
3
Optimal timing for intravenous administration set replacement.静脉输液器更换的最佳时机。
Cochrane Database Syst Rev. 2005 Oct 19(4):CD003588. doi: 10.1002/14651858.CD003588.pub2.
4
Higher versus lower amino acid intake in parenteral nutrition for newborn infants.新生儿肠外营养中较高与较低氨基酸摄入量的比较。
Cochrane Database Syst Rev. 2018 Mar 5;3(3):CD005949. doi: 10.1002/14651858.CD005949.pub2.
5
Exercise interventions for cerebral palsy.脑瘫的运动干预
Cochrane Database Syst Rev. 2017 Jun 11;6(6):CD011660. doi: 10.1002/14651858.CD011660.pub2.
6
Alternative versus Conventional Hemodialysis Regimen: One Size Does Not Fit All.替代与传统血液透析方案：并非一概而论。
Blood Purif. 2025;54(8):517-523. doi: 10.1159/000546452. Epub 2025 Jun 18.
7
Nutritional support for liver disease.肝病的营养支持
Cochrane Database Syst Rev. 2012 May 16;2012(5):CD008344. doi: 10.1002/14651858.CD008344.pub2.
8
Prophylactic anticoagulants for non-hospitalised people with COVID-19.COVID-19 非住院患者的预防性抗凝治疗。
Cochrane Database Syst Rev. 2023 Aug 16;8(8):CD015102. doi: 10.1002/14651858.CD015102.pub2.
9
Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis.胰高血糖素样肽-1受体激动剂的使用不会增加急性胰腺炎的风险，且与2型糖尿病并发急性胰腺炎患者较低的并发症发生率相关：一项多中心分析。
Am J Gastroenterol. 2025 May 13. doi: 10.14309/ajg.0000000000003525.
10
Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission.异基因造血细胞移植用于首次完全缓解的成人急性淋巴细胞白血病（ALL）。
Cochrane Database Syst Rev. 2011 Oct 5;2011(10):CD008818. doi: 10.1002/14651858.CD008818.pub2.
本文引用的文献
1
Influence of Obesity on the Safety and Efficacy of Antithrombotic Therapy: A Systematic Review and Meta-Analysis.肥胖对抗血栓治疗安全性和有效性的影响：一项系统评价和荟萃分析。
Arq Bras Cardiol. 2025 Apr;122(4):e20240544. doi: 10.36660/abc.20240544.
2
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2025年美国心脏病学会/美国心脏协会/美国急诊医师学会/美国急诊医疗服务医师学会/心血管造影和介入学会急性冠状动脉综合征患者管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
J Am Coll Cardiol. 2025 Jun 10;85(22):2135-2237. doi: 10.1016/j.jacc.2024.11.009. Epub 2025 Feb 27.
3
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
4
Brazilian Society of Cardiology Guidelines on Unstable Angina and Acute Myocardial Infarction without ST-Segment Elevation - 2021.巴西心脏病学会关于非ST段抬高型不稳定型心绞痛和急性心肌梗死的指南 - 2021年
Arq Bras Cardiol. 2021 Jul;117(1):181-264. doi: 10.36660/abc.20210180.
5
Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study.按 BMI 类别对病态肥胖患者进行依诺肝素治疗剂量分层：一项回顾性队列研究。
Clin Drug Investig. 2020 Jan;40(1):33-40. doi: 10.1007/s40261-019-00855-9.
6
Obesity and cardiovascular outcomes: a review.肥胖与心血管疾病结局：综述
Eur Heart J Acute Cardiovasc Care. 2016 Feb;5(1):77-85. doi: 10.1177/2048872614523349. Epub 2014 Feb 13.
7
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.非 ST 段抬高型急性冠脉综合征患者的肥胖问题：来自 SYNERGY 试验的结果。
Int J Cardiol. 2010 Mar 4;139(2):123-33. doi: 10.1016/j.ijcard.2008.10.008. Epub 2008 Nov 14.
8
Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.肥胖对Matisse试验中急性静脉血栓栓塞症患者接受磺达肝癸钠、依诺肝素或肝素治疗后结局的影响。
J Thromb Haemost. 2007 Jun;5(6):1191-4. doi: 10.1111/j.1538-7836.2007.02565.x.
9
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.依诺肝素与普通肝素联合纤溶治疗ST段抬高型心肌梗死的比较
N Engl J Med. 2006 Apr 6;354(14):1477-88. doi: 10.1056/NEJMoa060898. Epub 2006 Mar 14.
10
Excess weight at time of presentation of myocardial infarction is associated with lower initial mortality risks but higher long-term risks including recurrent re-infarction and cardiac death.心肌梗死发作时体重超标与较低的初始死亡风险相关，但与包括再发心肌梗死和心源性死亡在内的较高长期风险相关。
Int J Cardiol. 2006 Jun 16;110(2):153-9. doi: 10.1016/j.ijcard.2005.06.040. Epub 2005 Jul 25.
Zotero 插件